Threshold Pharmaceuticals (THLD) 4.03 $THLD
Threshold Pharmaceuticals Raises Cash - An Inside Look At The Deal
Red Acre Investments - Seeking Alpha - Thu Feb 12, 2:19PM CST
Threshold pharmaceuticals(NASDAQ: THLD ) announced pricing on a $30 million financing today. The company sold 8.3 million shares that each come with one warrant having a 5-year expiry, and an exercise price of $10.86. We present herein an analysis...
THLD: 4.03 (+0.21)
Threshold prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:00AM CST
THLD: 4.03 (+0.21)
Threshold Pharmaceuticals Announces Pricing of $30 Million Offering of Common Stock and Warrants
Marketwired - Thu Feb 12, 5:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the pricing of an underwritten offering of 8,300,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 8,300,000 shares of common stock. The combined offering price of each share of common stock and accompanying warrant was $3.62. The net proceeds to Threshold from this offering are expected to be approximately $28.2 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Threshold. Threshold expects to use the net proceeds from this offering for working capital and general corporate purposes, including research and development expenses, general and administrative expenses and manufacturing expenses.
THLD: 4.03 (+0.21)
In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 07, 6:24AM CST
Macrophages attaching to a cancer cell. Source: Dr. Raowf Guirguis via Wikimedia Commons . Cancer is the second-leading cause of death in the United States, and if projections from the World Health Organization are correct about a nearly 60%...
IMGN: 7.19 (unch), PPHM: 1.28 (+0.03), THLD: 4.03 (+0.21)
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More
at The Street - Thu Jan 29, 12:06PM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
TROV: 4.99 (-0.17), APRI: 1.84 (-0.08), THLD: 4.03 (+0.21)
AOL and Gilead Sciences are big market movers
AP - Tue Jan 06, 5:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 16.30 (-0.06), K.TO: 3.51 (-0.22), CS: 23.65 (+0.23), BBEP: 7.85 (+0.32), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), CYBX: 57.03 (+0.26), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), KGC: 2.81 (-0.17), AOL: 41.78 (+1.22), CVEO: 3.87 (+0.15), EBIX: 23.80 (+0.30), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), VZ: 49.31 (-0.21), XOOM: 15.77 (+0.64)
Hot Stock: Threshold Pharmaceuticals, Shares Gain 12.2% (THLD)
Comtex SmarTrend(R) - Mon Jan 05, 10:07AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's best performing low-priced stocks, up 12.2% to $3.85 on 1.3x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 698,000 shares, vs. average volume of 524,000 shares per day. The stock has outperformed the Dow (12.2% to the Dow's -1.2%) and outperformed the S&P 500 (12.2% to the S&P's -1.3%) during today's trading.
THLD: 4.03 (+0.21)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 90.70 (+0.93), BMRN: 100.76 (+1.98), TGTX: 13.13 (-0.19), BMY: 60.04 (+0.56), MACK: 10.22 (+0.40), FMI: 48.88 (+0.17), RNA: 18.65 (unch), GWPH: 78.09 (+1.70), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), ICPT: 209.12 (+7.12), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), NVS: 102.20 (-0.17)
Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD"
in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting
Marketwired - Sat Dec 06, 11:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade(R)) and low-dose dexamethasone ("TBorD" for the treatment of patients with relapsed/refractory multiple myeloma (MM). The median number of prior therapies was 8 (range, 4-12). The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses (one very good partial response and one partial response) were observed in 2 of 7 (29%) evaluable patients overall and 2 of 4 (50%) evaluable patients at the recommended phase 2 dose of TH-302. These data are being presented today at the 56th ASH Annual Meeting and Exposition in San Francisco, California (Abstract #2142).
THLD: 4.03 (+0.21)
Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in December 2014
Marketwired - Tue Nov 25, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference on December 2, 2014, at 11:30 a.m. Eastern Time and at the Oppenheimer 25th Annual Healthcare Conference on December 11, 2014, at 11:30 a.m. Eastern Time.
THLD: 4.03 (+0.21)
Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 5.66 (+0.06), BCRX: 10.06 (-0.09), AVNR: 16.96 (unch), ACAD: 34.21 (+0.37), IDRA: 4.10 (-0.14), QQQ: 106.91 (+0.91), SGEN: 31.57 (+0.36), XBI: 203.40 (+1.36), TGTX: 13.13 (-0.19), IBB: 323.46 (+3.04), THLD: 4.03 (+0.21), IWM: 121.53 (+0.72), TWTR: 48.50 (+0.55), XOMA: 3.41 (-0.01)
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
Marketwired - Mon Nov 17, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab (Avastin(R)) for the treatment of glioblastoma (GBM), the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only U.S. Food and Drug Administration (FDA)-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months.
THLD: 4.03 (+0.21)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 5.53 (+0.08), AGEN: 5.03 (-0.01), NVAX: 8.80 (+0.40), ALXN: 182.29 (+6.02), PPHM: 1.28 (+0.03), THLD: 4.03 (+0.21), GSK: 47.94 (+1.99), OMER: 20.63 (+0.13)
Alibaba and Ford are big market movers
AP - Tue Nov 11, 3:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 16.30 (-0.06), SFY: 2.91 (+0.26), THLD: 4.03 (+0.21), SFM: 38.38 (+0.53), ZNGA: 2.24 (-0.42), LUV: 43.30 (-0.20), DRI: 61.72 (+0.31), BABA: 89.05 (+1.95)
Threshold Pharma cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:30AM CST
THLD: 4.03 (+0.21)
Traders Get Bullish on Shares of Threshold Pharmaceuticals, Shares Up 8.2% (THLD)
Comtex SmarTrend(R) - Tue Nov 11, 10:11AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's best performing low-priced stocks, up 8.2% to $3.23 on 1.6x average daily volume. Threshold Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 756,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's 0.1%) and outperformed the S&P 500 (8.2% to the S&P's 0.1%) during today's trading.
THLD: 4.03 (+0.21)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:17AM CST
JRJC: 5.46 (+0.16), CODI: 16.61 (+0.03), RAX: 50.01 (+0.24), QIWI: 25.16 (+1.45), MCEP: 6.29 (+0.12), PHMD: 1.68 (+0.04), SFM: 38.38 (+0.53), VSLR: 8.39 (+0.06), VOD: 35.85 (+0.14), LITB: 5.55 (-0.13), PT: 0.83 (+0.04), THLD: 4.03 (+0.21), ZNGA: 2.24 (-0.42)
Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previously Untreated Patients With Metastatic or Locally Advanced Unresectable Soft Tissue Sarcoma
Marketwired - Tue Nov 11, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma (STS).
THLD: 4.03 (+0.21)
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conference
Marketwired - Mon Nov 10, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on November, 18, 2014, at 10:20 a.m. Eastern Time.
THLD: 4.03 (+0.21)
Threshold Pharmaceuticals Raises Cash - An Inside Look At The Deal
Red Acre Investments - Seeking Alpha - Thu Feb 12, 2:19PM CST
Threshold pharmaceuticals(NASDAQ: THLD ) announced pricing on a $30 million financing today. The company sold 8.3 million shares that each come with one warrant having a 5-year expiry, and an exercise price of $10.86. We present herein an analysis...
THLD: 4.03 (+0.21)
Threshold prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:00AM CST
THLD: 4.03 (+0.21)
Threshold Pharmaceuticals Announces Pricing of $30 Million Offering of Common Stock and Warrants
Marketwired - Thu Feb 12, 5:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the pricing of an underwritten offering of 8,300,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 8,300,000 shares of common stock. The combined offering price of each share of common stock and accompanying warrant was $3.62. The net proceeds to Threshold from this offering are expected to be approximately $28.2 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Threshold. Threshold expects to use the net proceeds from this offering for working capital and general corporate purposes, including research and development expenses, general and administrative expenses and manufacturing expenses.
THLD: 4.03 (+0.21)
In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 07, 6:24AM CST
Macrophages attaching to a cancer cell. Source: Dr. Raowf Guirguis via Wikimedia Commons . Cancer is the second-leading cause of death in the United States, and if projections from the World Health Organization are correct about a nearly 60%...
IMGN: 7.19 (unch), PPHM: 1.28 (+0.03), THLD: 4.03 (+0.21)
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More
at The Street - Thu Jan 29, 12:06PM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
TROV: 4.99 (-0.17), APRI: 1.84 (-0.08), THLD: 4.03 (+0.21)
AOL and Gilead Sciences are big market movers
AP - Tue Jan 06, 5:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 16.30 (-0.06), K.TO: 3.51 (-0.22), CS: 23.65 (+0.23), BBEP: 7.85 (+0.32), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), CYBX: 57.03 (+0.26), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), KGC: 2.81 (-0.17), AOL: 41.78 (+1.22), CVEO: 3.87 (+0.15), EBIX: 23.80 (+0.30), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), VZ: 49.31 (-0.21), XOOM: 15.77 (+0.64)
Hot Stock: Threshold Pharmaceuticals, Shares Gain 12.2% (THLD)
Comtex SmarTrend(R) - Mon Jan 05, 10:07AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's best performing low-priced stocks, up 12.2% to $3.85 on 1.3x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 698,000 shares, vs. average volume of 524,000 shares per day. The stock has outperformed the Dow (12.2% to the Dow's -1.2%) and outperformed the S&P 500 (12.2% to the S&P's -1.3%) during today's trading.
THLD: 4.03 (+0.21)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 90.70 (+0.93), BMRN: 100.76 (+1.98), TGTX: 13.13 (-0.19), BMY: 60.04 (+0.56), MACK: 10.22 (+0.40), FMI: 48.88 (+0.17), RNA: 18.65 (unch), GWPH: 78.09 (+1.70), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), ICPT: 209.12 (+7.12), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), NVS: 102.20 (-0.17)
Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD"
in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting Marketwired - Sat Dec 06, 11:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade(R)) and low-dose dexamethasone ("TBorD"
for the treatment of patients with relapsed/refractory multiple myeloma (MM). The median number of prior therapies was 8 (range, 4-12). The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses (one very good partial response and one partial response) were observed in 2 of 7 (29%) evaluable patients overall and 2 of 4 (50%) evaluable patients at the recommended phase 2 dose of TH-302. These data are being presented today at the 56th ASH Annual Meeting and Exposition in San Francisco, California (Abstract #2142). THLD: 4.03 (+0.21)
Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in December 2014
Marketwired - Tue Nov 25, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference on December 2, 2014, at 11:30 a.m. Eastern Time and at the Oppenheimer 25th Annual Healthcare Conference on December 11, 2014, at 11:30 a.m. Eastern Time.
THLD: 4.03 (+0.21)
Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 5.66 (+0.06), BCRX: 10.06 (-0.09), AVNR: 16.96 (unch), ACAD: 34.21 (+0.37), IDRA: 4.10 (-0.14), QQQ: 106.91 (+0.91), SGEN: 31.57 (+0.36), XBI: 203.40 (+1.36), TGTX: 13.13 (-0.19), IBB: 323.46 (+3.04), THLD: 4.03 (+0.21), IWM: 121.53 (+0.72), TWTR: 48.50 (+0.55), XOMA: 3.41 (-0.01)
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
Marketwired - Mon Nov 17, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab (Avastin(R)) for the treatment of glioblastoma (GBM), the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only U.S. Food and Drug Administration (FDA)-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months.
THLD: 4.03 (+0.21)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 5.53 (+0.08), AGEN: 5.03 (-0.01), NVAX: 8.80 (+0.40), ALXN: 182.29 (+6.02), PPHM: 1.28 (+0.03), THLD: 4.03 (+0.21), GSK: 47.94 (+1.99), OMER: 20.63 (+0.13)
Alibaba and Ford are big market movers
AP - Tue Nov 11, 3:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 16.30 (-0.06), SFY: 2.91 (+0.26), THLD: 4.03 (+0.21), SFM: 38.38 (+0.53), ZNGA: 2.24 (-0.42), LUV: 43.30 (-0.20), DRI: 61.72 (+0.31), BABA: 89.05 (+1.95)
Threshold Pharma cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:30AM CST
THLD: 4.03 (+0.21)
Traders Get Bullish on Shares of Threshold Pharmaceuticals, Shares Up 8.2% (THLD)
Comtex SmarTrend(R) - Tue Nov 11, 10:11AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's best performing low-priced stocks, up 8.2% to $3.23 on 1.6x average daily volume. Threshold Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 756,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's 0.1%) and outperformed the S&P 500 (8.2% to the S&P's 0.1%) during today's trading.
THLD: 4.03 (+0.21)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:17AM CST
JRJC: 5.46 (+0.16), CODI: 16.61 (+0.03), RAX: 50.01 (+0.24), QIWI: 25.16 (+1.45), MCEP: 6.29 (+0.12), PHMD: 1.68 (+0.04), SFM: 38.38 (+0.53), VSLR: 8.39 (+0.06), VOD: 35.85 (+0.14), LITB: 5.55 (-0.13), PT: 0.83 (+0.04), THLD: 4.03 (+0.21), ZNGA: 2.24 (-0.42)
Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previously Untreated Patients With Metastatic or Locally Advanced Unresectable Soft Tissue Sarcoma
Marketwired - Tue Nov 11, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma (STS).
THLD: 4.03 (+0.21)
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conference
Marketwired - Mon Nov 10, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on November, 18, 2014, at 10:20 a.m. Eastern Time.
THLD: 4.03 (+0.21)
